Why weight-loss jabs work better for some people than others

• Genetic variations in appetite and digestion genes predict differential weight-loss responses to GLP-1 receptor agonists (Wegovy, Mounjaro), suggesting personalised medicine approaches may optimise treatment selection
• Patients with specific genetic profiles may achieve substantially greater weight loss with these medications, indicating potential for pre-treatment genetic screening to identify responders
• Understanding individual genetic factors could improve patient counselling on realistic weight-loss expectations and help identify those who may require alternative or combined obesity interventions

People who carry variations in two genes linked to appetite and digestion can lose more weight when taking drugs such as Wegovy and Mounjaro to treat obesity, research suggests.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.